Literature DB >> 19164286

Dissecting the mechanisms of tissue transglutaminase-induced cross-linking of alpha-synuclein: implications for the pathogenesis of Parkinson disease.

Adrien W Schmid1, Diego Chiappe, Vérène Pignat, Valerie Grimminger, Ivan Hang, Marc Moniatte, Hilal A Lashuel.   

Abstract

Tissue transglutaminase (tTG) has been implicated in the pathogenesis of Parkinson disease (PD). However, exactly how tTG modulates the structural and functional properties of alpha-synuclein (alpha-syn) and contributes to the pathogenesis of PD remains unknown. Using site-directed mutagenesis combined with detailed biophysical and mass spectrometry analyses, we sought to identify the exact residues involved in tTG-catalyzed cross-linking of wild-type alpha-syn and alpha-syn mutants associated with PD. To better understand the structural consequences of each cross-linking reaction, we determined the effect of tTG-catalyzed cross-linking on the oligomerization, fibrillization, and membrane binding of alpha-syn in vitro. Our findings show that tTG-catalyzed cross-linking of monomeric alpha-syn involves multiple cross-links (specifically 2-3). We subjected tTG-catalyzed cross-linked monomeric alpha-syn composed of either wild-type or Gln --> Asn mutants to sequential proteolysis by multiple enzymes and peptide mapping by mass spectrometry. Using this approach, we identified the glutamine and lysine residues involved in tTG-catalyzed intramolecular cross-linking of alpha-syn. These studies demonstrate for the first time that Gln(79) and Gln(109) serve as the primary tTG reactive sites. Mutating both residues to asparagine abolishes tTG-catalyzed cross-linking of alpha-syn and tTG-induced inhibition of alpha-syn fibrillization in vitro. To further elucidate the sequence and structural basis underlying these effects, we identified the lysine residues that form isopeptide bonds with Gln(79) and Gln(109). This study provides mechanistic insight into the sequence and structural basis of the inhibitory effects of tTG on alpha-syn fibrillogenesis in vivo, and it sheds light on the potential role of tTG cross-linking on modulating the physiological and pathogenic properties of alpha-syn.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19164286      PMCID: PMC2676045          DOI: 10.1074/jbc.M809067200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

1.  Mitochondrial aconitase is a transglutaminase 2 substrate: transglutamination is a probable mechanism contributing to high-molecular-weight aggregates of aconitase and loss of aconitase activity in Huntington disease brain.

Authors:  Soo-Youl Kim; Lyuben Marekov; Parvesh Bubber; Susan E Browne; Irina Stavrovskaya; Jongmin Lee; Peter M Steinert; John P Blass; M Flint Beal; Gary E Gibson; Arthur J L Cooper
Journal:  Neurochem Res       Date:  2005-10       Impact factor: 3.996

2.  Deposition of detergent-resistant neurofilaments into Lewy body fibrils.

Authors:  M S Pollanen; C Bergeron; L Weyer
Journal:  Brain Res       Date:  1993-02-12       Impact factor: 3.252

3.  Familial Parkinson's disease. The awakening of alpha-synuclein.

Authors:  M Goedert
Journal:  Nature       Date:  1997-07-17       Impact factor: 49.962

4.  Tau is modified by tissue transglutaminase in situ: possible functional and metabolic effects of polyamination.

Authors:  J Tucholski; J Kuret; G V Johnson
Journal:  J Neurochem       Date:  1999-11       Impact factor: 5.372

5.  Cross-linking of a synthetic partial-length (1-28) peptide of the Alzheimer beta/A4 amyloid protein by transglutaminase.

Authors:  K Ikura; K Takahata; R Sasaki
Journal:  FEBS Lett       Date:  1993-07-12       Impact factor: 4.124

6.  Phosphorylation at Ser-129 but not the phosphomimics S129E/D inhibits the fibrillation of alpha-synuclein.

Authors:  Katerina E Paleologou; Adrian W Schmid; Carla C Rospigliosi; Hai-Young Kim; Gonzalo R Lamberto; Ross A Fredenburg; Peter T Lansbury; Claudio O Fernandez; David Eliezer; Markus Zweckstetter; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2008-03-14       Impact factor: 5.157

7.  Effect of tissue transglutaminase on the solubility of proteins containing expanded polyglutamine repeats.

Authors:  T-S Lai; T Tucker; J R Burke; W J Strittmatter; C S Greenberg
Journal:  J Neurochem       Date:  2004-03       Impact factor: 5.372

8.  Tissue transglutaminase catalyzes the formation of alpha-synuclein crosslinks in Parkinson's disease.

Authors:  G Andringa; K Y Lam; M Chegary; X Wang; T N Chase; M C Bennett
Journal:  FASEB J       Date:  2004-03-04       Impact factor: 5.191

9.  A structural and functional role for 11-mer repeats in alpha-synuclein and other exchangeable lipid binding proteins.

Authors:  Robert Bussell; David Eliezer
Journal:  J Mol Biol       Date:  2003-06-13       Impact factor: 5.469

10.  Tissue transglutaminase modulates alpha-synuclein oligomerization.

Authors:  Ine M J Segers-Nolten; Micha M M Wilhelmus; Gertjan Veldhuis; Bart D van Rooijen; Benjamin Drukarch; Vinod Subramaniam
Journal:  Protein Sci       Date:  2008-05-27       Impact factor: 6.725

View more
  10 in total

1.  Keratin 8 phosphorylation regulates its transamidation and hepatocyte Mallory-Denk body formation.

Authors:  Raymond Kwan; Shinichiro Hanada; Masaru Harada; Pavel Strnad; Daniel H Li; M Bishr Omary
Journal:  FASEB J       Date:  2012-02-23       Impact factor: 5.191

2.  Tissue transglutaminase-mediated glutamine deamidation of beta-amyloid peptide increases peptide solubility, whereas enzymatic cross-linking and peptide fragmentation may serve as molecular triggers for rapid peptide aggregation.

Authors:  Adrien W Schmid; Enrico Condemi; Gabriele Tuchscherer; Diego Chiappe; Manfred Mutter; Horst Vogel; Marc Moniatte; Yury O Tsybin
Journal:  J Biol Chem       Date:  2011-02-07       Impact factor: 5.157

3.  Parkinson disease mutant E46K enhances α-synuclein phosphorylation in mammalian cell lines, in yeast, and in vivo.

Authors:  Martial Kamdem Mbefo; Mohamed-Bilal Fares; Katerina Paleologou; Abid Oueslati; Guowei Yin; Sandra Tenreiro; Madalena Pinto; Tiago Outeiro; Markus Zweckstetter; Eliezer Masliah; Hilal A Lashuel
Journal:  J Biol Chem       Date:  2015-02-05       Impact factor: 5.157

4.  Transglutaminase-mediated intramolecular cross-linking of membrane-bound alpha-synuclein promotes amyloid formation in Lewy bodies.

Authors:  Zoltán Nemes; Goran Petrovski; Maarten Aerts; Kjell Sergeant; Bart Devreese; László Fésüs
Journal:  J Biol Chem       Date:  2009-08-03       Impact factor: 5.157

5.  E46K Parkinson's-linked mutation enhances C-terminal-to-N-terminal contacts in alpha-synuclein.

Authors:  Carla C Rospigliosi; Sebastian McClendon; Adrian W Schmid; Trudy F Ramlall; Patrick Barré; Hilal A Lashuel; David Eliezer
Journal:  J Mol Biol       Date:  2009-04-05       Impact factor: 5.469

6.  Transglutaminase 2 exacerbates α-synuclein toxicity in mice and yeast.

Authors:  Hilary Grosso; Jong-Min Woo; Kang-Woo Lee; Joo-Young Im; Eliezer Masliah; Eunsung Junn; M Maral Mouradian
Journal:  FASEB J       Date:  2014-06-26       Impact factor: 5.191

7.  Transglutaminase activation in neurodegenerative diseases.

Authors:  Thomas M Jeitner; Nancy A Muma; Kevin P Battaile; Arthur Jl Cooper
Journal:  Future Neurol       Date:  2009-07-01

Review 8.  New insight into transglutaminase 2 and link to neurodegenerative diseases.

Authors:  Boram Min; Kwang Chul Chung
Journal:  BMB Rep       Date:  2018-01       Impact factor: 4.778

9.  Absence of tissue transglutaminase reduces amyloid-beta pathology in APP23 mice.

Authors:  Micha M M Wilhelmus; Osoul Chouchane; Maarten Loos; Cornelis A M Jongenelen; John J P Brevé; Allert Jonker; John G J M Bol; August B Smit; Benjamin Drukarch
Journal:  Neuropathol Appl Neurobiol       Date:  2022-02-23       Impact factor: 6.250

Review 10.  Implication of Alpha-Synuclein Phosphorylation at S129 in Synucleinopathies: What Have We Learned in the Last Decade?

Authors:  Abid Oueslati
Journal:  J Parkinsons Dis       Date:  2016       Impact factor: 5.568

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.